Skip to main content

Table 3 Adverse events (all grades, occurring in >10% of patients). Total number of patients N = 25

From: Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

 

Grade

1

2

3

4

All

N

N

N

N

N

%

Fatigue

6

6

1

0

13

52.0

Hypertension

4

6

2

0

12

48.0

Anorexia

8

3

0

0

11

44.0

Nausea

11

0

0

0

11

44.0

Asthenia

6

4

0

0

10

40.0

Diarrhea

8

1

1

0

10

40.0

Dysphonia

10

0

0

0

10

40.0

Vomiting

7

2

1

0

10

40.0

Thrombocytopenia

3

2

3

0

8

32.0

Headache

6

0

0

0

6

24.0

Abdominal pain

2

2

2

0

6

24.0

Dysgeusia

4

2

0

0

6

24.0

Myalgia

5

1

0

0

6

24.0

Neck pain

4

1

0

0

5

20.0

Hypothyroidism

3

2

0

0

5

20.0

Proteinuria

0

3

2

0

5

20.0

Dry skin

4

1

0

0

5

20.0

Arthralgia

3

1

0

0

4

16.0

Elevated bilirubin

0

4

0

0

4

16.0

Muscular contractures

4

0

0

0

4

16.0

Hair modified color

4

0

0

0

4

16.0

Epistaxis

4

0

0

0

4

16.0

Hemorrhoids

3

1

0

0

4

16.0

Microangiopathy

0

0

4

0

4

16.0

Paresthesia

4

0

0

0

4

16.0

Stomatitis

2

2

0

0

4

16.0

Hand & foot syndrome

3

0

1

0

4

16.0

Mucositis

3

1

0

0

4

16.0

Elevated AST

2

1

0

0

3

12.0

Back pain

2

1

0

0

3

12.0

Musculoskeletal pain

2

1

0

0

3

12.0

Thoracic musculoskeletal pain

0

1

2

0

3

12.0

Dyspnea

3

0

0

0

3

12.0

Urinary tract infection

0

3

0

0

3

12.0

Neutropenia

0

3

0

0

3

12.0